Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 2

Sponsor Class

NETWORK 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Breast Neoplasms 1931Neoplasms 1385Carcinoma, Non-Small-Cell Lung 1324Prostatic Neoplasms 1070Multiple Myeloma 855Leukemia, Myeloid, Acute 759Neoplasm Metastasis 691Colorectal Neoplasms 676Melanoma 666Lung Neoplasms 665Lymphoma 655Leukemia 591Lymphoma, Non-Hodgkin 587Leukemia, Lymphocytic, Chronic, B-Cell 529Ovarian Neoplasms 517Pancreatic Neoplasms 493Precursor Cell Lymphoblastic Leukemia-Lymphoma 471Recurrence 466Myelodysplastic Syndromes 421Lymphoma, Follicular 407Head and Neck Neoplasms 401Glioblastoma 376Carcinoma, Renal Cell 375Lymphoma, Large B-Cell, Diffuse 372Brain Neoplasms 370Hodgkin Disease 352Carcinoma, Hepatocellular 324Squamous Cell Carcinoma of Head and Neck 323Lymphoma, Mantle-Cell 302Sarcoma 281

Interventions

Docetaxel 2Androgen Antagonists 2darolutamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Has results × Metastatic Hormone-sensitive Prostate Cancer × Clear all
NCT00309985 2025-12-11

CHAARTED

Eastern Cooperative Oncology Group

Phase 3 Completed
790 enrolled 11 charts
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer

NCT02799602 2025-12-04

ARASENS

Bayer

Phase 3 Completed
1,306 enrolled 25 charts 2 FDA
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡